# Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

> **NCT00039104** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** rebimastat
- **DRUG:** zoledronic acid
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00039104
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2005-01
- **Final completion:** —
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00039104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00039104, "Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00039104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*